Skip to main content
. 2021 May 6;100(8):101233. doi: 10.1016/j.psj.2021.101233

Table 5.

Pooled effects obtained in meta-analysis models for percentage of optimal anticoccidial activity (POAA).

Classification CI 95%
Challenge Treatment Pooled effects (%) R/PR/S Lower Upper I2 and P-value heterogeneity
E. acervulina Overall 22.45 R 13.8 31.1 74%, P < 0.01
Lasalocid 33.09 R −1.27 67.4 86%, P < 0.01
Maduramycin 6.60 R −6.55 19.7 0%, P = 0
Decoquinate 47.07 R 25.6 68.5 68%, P = 0
Nicarbazin+semduramicin 18.62 R 6.3 30.9 0%, P = 0
Monensin 7.06 R −11.4 25.5 48%, P =0
Salinomycin 21.63 R −4.04 47.3 74%, P = 0
Narasin+Nicarbazin 18.80 R 6.30 31.3 0%, P = 0
Nicarbazin 23.72 R 0.21 47.2 70%, P = 0
E. maxima Overall 47.27 R 39.2 55.3 92%, P < 0.01
Lasalocid 65.9 PR 36.7 95.1 92%, P = 0
Maduramycin 40.2 R 3.83 76.6 95%, P = 0
Decoquinate 81.8 S 53.3 110.3 91%, P = 0
Nicarbazin+semduramicin 34.0 R 25.6 42.4 27%, P = 0
Monensin 24.6 R -−19.1 68.4 96%, P = 0
Salinomycin 41.6 R 35.1 48.2 0%, P = 0
Narasin+Nicarbazin 49.4 R 26.8 72.1 87%, P = 0
Nicarbazin 41.8 R 35.7 47.9 0%, P =0

CI: Confidence interval; I2: I-square test percentual and P-value of this. I-square is a heterogeneity test that evaluates if the differences between measures are random or more than expected. When heterogeneity is significant (I-square > 70–80% and/or P < 0.05), random effect models were used to calculate pooled effect. When not significant, fixed effect models were used. This procedure is necessary not to validate the results obtained, but to validate methods used to combine them. Significant or not significant differences between pooled effects of each compound can be evaluated by comparing confidence intervals and their intersections. Significant differences are when there is no intersections between CI.

Abbreviations: PR, Partially Resistant; R, Resistant; S, Sensitive.